Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sales Rep Overtime Might Get Supreme Court Review; "Staggering Retroactive Liability" Is Worry

This article was originally published in The Pink Sheet Daily

Executive Summary

The court will consider certiorari petitions from Novartis and Schering at its Feb. 18 conference. An amicus brief from PhRMA paints a dire picture.

You may also be interested in...



Sales Rep Overtime Issue Remains Unresolved As Supreme Court Declines To Review Novartis, Merck Rulings

Despite a split in circuit courts as to whether sales reps are exempt from overtime pay, the Supreme Court denied certiorari petitions; companies may have to change their overtime compensation systems.

Sales Rep Overtime Issue Remains Unresolved As Supreme Court Declines To Review Novartis, Merck Rulings

Despite a split in circuit courts as to whether sales reps are exempt from overtime pay, the Supreme Court denied certiorari petitions; companies may have to change their overtime compensation systems.

AstraZeneca’s Vimovo Sales Reps Share Detailing Work With Call Center, Website

Fewer AstraZeneca sales representatives may be knocking on physician doors to promote the company’s new arthritis drug Vimovo (naproxen/esomeprazole) compared to previous drug launches.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS071919

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel